Daisuke Ogiya

Dr. Daisuke Ogiya

Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Rikio SuzukiRikio Suzuki
Rikio Suzuki
DODaisuke Ogiya
Daisuke Ogiya
YOYoshiaki Ogawa
Yoshiaki Ogawa
HKHiroshi Kawada
Hiroshi Kawada
KAKiyoshi Ando
Kiyoshi Ando
The prognosis of patients with multiple myeloma (MM) has improved dramatically with the introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant, following an intractable and incurable course. A myeloma niche (MM niche) develops in the bone marrow microenvironment and plays an important role in the drug resistance mechanism of MM. In particular, adhesion between MM cells and bone marrow stromal cells mediated by adhesion molecules induces cell adhesion-mediated drug resistance (CAM-DR). Analyses of the role of mitochondria in cancer cells, including MM cells, has revealed that the mechanism leading to drug resistance involves exchange of mitochondria between cells (mitochondrial transfer) via tunneling nanotubes (TNTs) within the MM niche. Here, we describe the discovery of these drug resistance mechanisms and the identification of promising therapeutic agents primarily targeting CAM-DR, mitochondrial transfer, and TNTs.